A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 465-471

  Nuijten, Mark J C ^a   de Castro Carpeño, Javier ^b   Chouaid, Christos ^c   Vergnenègre, Alain ^d   Grossi, Francesco ^e   Bischoff, Helge ^f   Heigener, David ^g   Walzer, Stefan ^h  

^a Ars Accessus Medica   (Netherlands)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HÔPITAL SAINT ANTOINE   (France)

^d Hopital du Cluzeau   (France)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g KRANKENHAUS GROSSHANSDORF   (Germany)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cost comparison; Erlotinib; First line maintenance; Lung cancer; Non small cell lung cancer; Pemetrexed

Indexed keywords

ERLOTINIB; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIARRHEA; DRUG COST; FATIGUE; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HUMAN; INFECTION; INFESTATION; ITALY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SPAIN; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COSTS; FEMALE; FRANCE; GERMANY; GLUTAMATES; GUANINE; HUMANS; ITALY; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SPAIN;

EID: 84860505525     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.005     Document Type: Article

References (24)

1. European Medicines Agency. Alimta Scientific Discussion, Available from: 2009 [accessed 20.01.11]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000564/WC500025610.pdf.
2. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
3. Brodowicz T., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
4. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
5. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
6. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer v.2, Available from: 2010 [accessed 25.01.11]. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
7. European Medicines Agency. Avastin summary of product characteristics, Available from: 2009 [accessed 15.12.10]. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf.
8. Gridelli C., Maione P., Rossi A., Ferrara M.L., Bareschino M.A., Schettino C., et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. Oncologist 2009, 14:137-147.
9. Grossi F., Aita M., Follador A., Defferrari C., Brianti A., Sinaccio G., et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007, 12:451-464.
10. Rinaldi M., Belvedere O., Cauchi C., Defferrari C., Viola G., Grossi F. Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol 2006, 17(Suppl. 2):ii67-ii70.
11. Mok T.S., Ramalingam S.S. Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 2009, 115:5143-5154.
12. European Medicines Agency. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Alimta, Available from: 2009 [accessed 21.01.11]. http://www.emea.europa.eu/pdfs/human/opinion/Alimta_9292908en.pdf.
13. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
14. Banz K., Bischoff H., Brunner M., Chouaid C., de Castro Carpeño J., de Marinis F., et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 2011, May 16 [Epub ahead of print].
15. Official Gazette. GHS 9606 - Chimiothérapie pour tumeurs, en séance, Available from: 2010 [accessed 20.01.11]. http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=244B4669551731582BF775EC93B44BD2.tpdjo09v_2?cidTexte=JORFTEXT000021879531%26dateTexte=%26oldAction=rechJO%26categorieLien=id.
16. Diario Oficial de Galicia. Decreto 164/2008, de 17 de julio, por el que se establecen las tarifas de los servicios sanitarios prestados en los centros dependientes del Servicio Gallego de Salud y en las fundaciones públicas sanitarias. 2008;150:15.060-15.074.
17. Conferenza delle Regioni e delle Province Autonome. Tariffa unica convenzionale per le prestazioni di assistenza ospedaliera regole e tariffe valide per l'anno 2009, Available from: 2010 [accessed 22.01.11]. http://www.regioni.it/upload/270110TUC_ASSISTENZA_OSPEDALIERA.pdf.
18. Gatzemeier U., Pirk O., Gabriel A., Kotowa W., Heigener D. Second-line-therapy for non-small cell lung cancer (NSCLC) - a retrospective cost analysis. TumorDiagn Ther 2008, 29:211-217.
19. Borner M., Scheithauer W., Twelves C., Maroun J., Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 2001, 6(Suppl. 4):12-16.
20. Lau P.M., Stewart K., Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?. Support Care Cancer 2004, 12:626-633.
21. Jaehde U., Liekweg A., Simons S., Westfeld M. Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci 2008, 30:161-168.
22. Mickisch G., Gore M., Escudier B., Procopio G., Walzer S., Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. Br J Cancer 2010, 102:80-86.
23. Ciuleanu T, Stelmakh L, Cicenas S, Esteban E. Erlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III TITAN study. Abstract LBOA5 presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, USA, 9-11 December 2010.
24. Vamvakas L, Agelaki S, Kentepozidis NK, Karampeazis A, Pallis AG, Christophyllakis C, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. Abstract 7519 presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, 4-8 June 2010.